

November 24, 2025

The Honorable Shelley Moore Capito
Chair
Senate Appropriations Committee
Subcommittee on Labor-HHS-Education
United States Senate
Washington, DC 20510

The Honorable Tammy Baldwin
Ranking Member
Senate Appropriations Committee
Subcommittee on Labor-HHS-Education
United States Senate
Washington, DC 20510

The Honorable Robert Aderholt
Chair
House Appropriations Committee
Subcommittee on Labor-HHS-Education
United States House of Representatives
Washington, DC 20515

The Honorable Rosa DeLauro
Ranking Member
House Appropriations Committee
Subcommittee on Labor-HHS-Education
United States House of Representatives
Washington, DC 20515

Dear Chair Capito, Ranking Member Baldwin, Chair Aderholt, and Ranking Member DeLauro,

The undersigned organizations thank you for your leadership and hard work as the Fiscal Year 2026 (FY26) appropriations process continues. As you work to finalize FY26 funding levels for the Labor, Health and Human Services, Education, and Related Agencies bill, we respectfully urge you to provide at least \$1.5 billion for the Advanced Research Projects Agency for Health (ARPA-H) in a manner that supplements, rather than supplants, funding for the National Institutes of Health (NIH) and other health-related agencies within the Labor-HHS-Education Appropriations Bill.

Congress established ARPA-H in 2022 to complement NIH's pivotal role by focusing on projects that fall outside the realm of current public and private funding streams. These projects, which focus on high-risk, high-reward, end-product-driven research and development, are designed to cross scientific and engineering disciplines to accelerate health breakthroughs. ARPA-H selects bold, high-impact projects, sets concrete milestones, and terminates projects that fail to deliver, ensuring accountability while creating the opportunity for major innovation. In just a few years, ARPA-H has identified and launched 25 programs, funded nearly 160 projects, and built a network of over 1,800 health innovation partners across all 50 states. These ambitious and unique efforts—focused on pursuing the best opportunities for impact and ensuring market translation—target massively important, but unmet, needs. Examples include:

- [**PRINT**](#), developing safe, bioprinted organs for patients who need transplants.
- [**PROSPR**](#), uncovering the root causes of aging and chronic disease to help people stay healthier for longer.
- [**TARGET**](#), accelerating the discovery of new antibiotics that can treat drug-resistant infections.
- [**RAPID**](#), using AI to help doctors diagnose rare diseases in weeks instead of years; and
- [**PARADIGM**](#), bringing mobile clinics and advanced care directly to rural communities.

ARPA-H programs have already begun to deliver results to patients. In April, ARPA-H awardee Satio, Inc. announced the development of [Digital SatioRx](#), a low-cost, remotely controllable, reusable intradermal drug delivery device that enables improved patient care in telehealth and home healthcare settings. Researchers supported by ARPA-H at the [University of Miami](#) have already made major steps to develop a device that will be critical for the success of whole eye transplants. ARPA-H-supported [researchers at Stanford](#) have created new tools to 3D print the complex vascular trees needed to carry blood throughout a bioprinted organ, such as a heart.

ARPA-H is building momentum while delivering results. We urge you to sustain a budget of \$1.5 billion for ARPA-H, supporting its continued commitment to work at a rapid pace, finding and funding projects that break the mold and present a highly promising path to overcoming health challenges, from chronic conditions to fast-moving global threats.

Thank you again for your leadership and service, and please extend our appreciation to your respective staff members.

Sincerely,

[Organizations listed alphabetically]